Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Mersana Therapeutics (NASDAQ: MRSN) is a clinical-stage biopharmaceutical company dedicated to discovering and developing next-generation antibody-drug conjugates (ADCs) for cancer patients. Utilizing its differentiated and proprietary ADC platforms, such as Dolaflexin and Dolasynthen, Mersana aims to create ADCs with optimal efficacy, safety, and tolerability. The company is focused on advancing its pipeline of targeted cancer therapies, driven by a commitment to scientific innovation and a patient-centric approach to address unmet medical needs in oncology.
Serves as the central hub for Mersana's research and development, clinical operations, corporate strategy, and administrative functions, focusing on advancing its pipeline of antibody-drug conjugates (ADCs).
State-of-the-art laboratory and research facilities tailored for ADC development and biopharmaceutical innovation. The location is part of a vibrant life sciences campus.
Characterized by a collaborative, innovative, and patient-focused environment. Employees are driven by scientific excellence, a sense of urgency, and a shared mission to impact the lives of cancer patients. The culture encourages teamwork, open communication, and continuous learning.
Strategically located in Cambridge, Massachusetts, a leading global epicenter for biotechnology and pharmaceutical research. This provides access to a rich ecosystem of talent, academic institutions, and potential industry collaborators, fostering innovation and growth.
While headquartered in Cambridge, MA, USA, Mersana Therapeutics has a global reach primarily through its clinical development activities. The company conducts and plans clinical trials for its ADC candidates in multiple countries, collaborating with international research institutions, clinical sites, and investigators to advance its therapies for cancer patients worldwide. Strategic partnerships and collaborations may further extend its operational and scientific presence globally.
840 Memorial Drive
Cambridge
MA
USA
No additional office locations available.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Mersana Therapeutics' leadership includes:
Mersana Therapeutics has been backed by several prominent investors over the years, including:
Over the past 12 months, Mersana Therapeutics has experienced key leadership transitions, including the appointment of a new CEO and a new CMO, reflecting a period of strategic refocusing for the company.
Discover the tools Mersana Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Mersana Therapeutics typically uses a standard corporate email format. The most commonly observed pattern is the first initial of the employee's first name followed by their full last name, all before the '@mersana.com' domain.
[first_initial][last_name]@mersana.com
Format
jdoe@mersana.com
Example
85%
Success rate
Mersana Therapeutics | Investor Relations • May 9, 2024
Mersana Therapeutics announced its Q1 2024 financial results, highlighting progress with its ADC candidates XMT-1660 and XMT-2056. The company reaffirmed its strategic focus on these programs following its 2023 restructuring and provided updates on clinical trial enrollment and anticipated data presentations....more
Mersana Therapeutics | Investor Relations • April 8, 2024
Mersana announced it would present preclinical data for XMT-1660, its Dolasynthen ADC targeting B7-H4, at the AACR 2024. The data showcased XMT-1660's potential in various solid tumors, including favorable pharmacokinetics and anti-tumor activity....more
Mersana Therapeutics | Investor Relations • February 28, 2024
The company reported its Q4 and full-year 2023 financial results, outlining its strategic priorities focused on XMT-1660 and XMT-2056. Mersana also discussed progress in its clinical development programs following the corporate restructuring undertaken in 2023....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Mersana Therapeutics, are just a search away.